现代妇产科进展
現代婦產科進展
현대부산과진전
CURRENT ADVANCES IN OBSTETRICS AND GYNECOLOGY
2015年
4期
255-258
,共4页
紫杉醇%卡铂%卵巢癌%免疫功能%CTL转输
紫杉醇%卡鉑%卵巢癌%免疫功能%CTL轉輸
자삼순%잡박%란소암%면역공능%CTL전수
Paclitaxel%Carboplatin%Ovarian cancer%Immune function%Adoptive trans-fer CTL
目的：：采用荷瘤动物模型经化疗联合被动免疫治疗,初步探讨化疗免疫“窗口期”对卵巢癌免疫应答的影响及其可能的免疫学机制。方法：以荷瘤大鼠为研究对象,根据紫杉醇联合卡铂对荷瘤鼠免疫功能改变的不同时期给予 CTL ( cytotoxic T-lympho-cyte)主动免疫治疗。观察荷瘤体积及机体免疫微环境改变。结果：荷瘤鼠紫杉醇和卡铂化疗后不同时期给予CTL转输治疗,其中化疗后第6天即淋巴细胞数最少期,给予免疫治疗,肿瘤生长最缓慢；CT扫描结果示,化疗后6天+免疫治疗组的瘤体积最小,且与其余治疗组有统计学意义。荷瘤鼠免疫功能示,化疗后6天+免疫治疗组中淋巴细胞抗原特异性增殖及CD8+T 细胞最明显,而Treg ( T-Lymphocytes, Regulatory )细胞明显降低。结论：紫杉醇和卡铂联合CTL治疗肿瘤具有协同作用,其中化疗后6天(即淋巴细胞降到最低期)是CTL免疫治疗的最佳时间点。化疗造成的肿瘤个体免疫功能的低下或是免疫系统空间的释放(所谓的免疫“窗口期”)为诱导特异性的抗肿瘤免疫应答提供了可能,免疫状态的检测是保证肿瘤患者化疗联合免疫治疗方案治疗有效性的重要前提之一。
目的：：採用荷瘤動物模型經化療聯閤被動免疫治療,初步探討化療免疫“窗口期”對卵巢癌免疫應答的影響及其可能的免疫學機製。方法：以荷瘤大鼠為研究對象,根據紫杉醇聯閤卡鉑對荷瘤鼠免疫功能改變的不同時期給予 CTL ( cytotoxic T-lympho-cyte)主動免疫治療。觀察荷瘤體積及機體免疫微環境改變。結果：荷瘤鼠紫杉醇和卡鉑化療後不同時期給予CTL轉輸治療,其中化療後第6天即淋巴細胞數最少期,給予免疫治療,腫瘤生長最緩慢；CT掃描結果示,化療後6天+免疫治療組的瘤體積最小,且與其餘治療組有統計學意義。荷瘤鼠免疫功能示,化療後6天+免疫治療組中淋巴細胞抗原特異性增殖及CD8+T 細胞最明顯,而Treg ( T-Lymphocytes, Regulatory )細胞明顯降低。結論：紫杉醇和卡鉑聯閤CTL治療腫瘤具有協同作用,其中化療後6天(即淋巴細胞降到最低期)是CTL免疫治療的最佳時間點。化療造成的腫瘤箇體免疫功能的低下或是免疫繫統空間的釋放(所謂的免疫“窗口期”)為誘導特異性的抗腫瘤免疫應答提供瞭可能,免疫狀態的檢測是保證腫瘤患者化療聯閤免疫治療方案治療有效性的重要前提之一。
목적：：채용하류동물모형경화료연합피동면역치료,초보탐토화료면역“창구기”대란소암면역응답적영향급기가능적면역학궤제。방법：이하류대서위연구대상,근거자삼순연합잡박대하류서면역공능개변적불동시기급여 CTL ( cytotoxic T-lympho-cyte)주동면역치료。관찰하류체적급궤체면역미배경개변。결과：하류서자삼순화잡박화료후불동시기급여CTL전수치료,기중화료후제6천즉림파세포수최소기,급여면역치료,종류생장최완만；CT소묘결과시,화료후6천+면역치료조적류체적최소,차여기여치료조유통계학의의。하류서면역공능시,화료후6천+면역치료조중림파세포항원특이성증식급CD8+T 세포최명현,이Treg ( T-Lymphocytes, Regulatory )세포명현강저。결론：자삼순화잡박연합CTL치료종류구유협동작용,기중화료후6천(즉림파세포강도최저기)시CTL면역치료적최가시간점。화료조성적종류개체면역공능적저하혹시면역계통공간적석방(소위적면역“창구기”)위유도특이성적항종류면역응답제공료가능,면역상태적검측시보증종류환자화료연합면역치료방안치료유효성적중요전제지일。
Objective:To evaluate the influence of synergistic antitumor activity on the immunologic response of ovarian cancer,and investigate the immunologic mechanism behind it, by applying chemotherapy combined with immunotherapy on the treatment of rat-bearing tumors. Methods:By applying adoptive immunotherapy with CTL to rat-bearing tumors at differ-ent time of the change of immunocyte number and immune function from established tumor treatment with paclitaxel and carboplatin chemotherapy, observe the changes of the volume of the established tumor and the immune function of different groups. Results:The combination at the 6th post-chemotherapy day with CTL led to the most significantly delayed tumor growth. In this group,the number of CD8+T cell was the highest,while the expression of Treg cell was the lowest. Conclusions:Paclitaxel and carboplatin chemotherapy has synergistic effects with adop-tive transfer of CTLs. It is optimal to apply the immune therapy against tumors at 6 days after chemotherapy. The lowest number of lymphocytes in the animal periphery might represent the optimal checkpoint for the immune therapy. Therefore,monitoring the immune status of tumor patients might become one of the important prerequisites for effective immune therapy when de-signing the comprehensive therapeutic strategies.
